Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma

被引：4
作者：
Basu, S. [1 ]
Tiwari, B. P. [1 ]
机构：
[1] Tata Mem Hosp Annexe, Bhabha Atom Res Ctr, Radiat Med Ctr, Mumbai, Maharashtra, India
来源：
INDIAN JOURNAL OF CANCER | 2011年 / 48卷 / 04期
关键词：
POSITRON-EMISSION-TOMOGRAPHY; BONE-MARROW; CANCER; METASTASIS;
D O I：
10.4103/0019-509X.92247
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：513 / U
页数：2
相关论文
共 6 条
[1]   Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET [J].
Basu, Sandip ;
Torigian, Drew ;
Alavi, Abass .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (03) :465-471
[2]  
Basu S, 2007, J CLIN ONCOL, V25, P1297, DOI 10.1200/JCO.2006.10.0123
[3]   Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer [J].
Meirelles, Gustavo S. P. ;
Schoeder, Heiko ;
Ravizzini, Gregory C. ;
Goenen, Mithat ;
Fox, Josef J. ;
Humm, John ;
Morris, Michael J. ;
Scher, Howard I. ;
Larson, Steven M. .
CLINICAL CANCER RESEARCH, 2010, 16 (24) :6093-6099
[4]   Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimiorotubule chemotherapy [J].
Morris, MJ ;
Akhurst, T ;
Larson, SM ;
Ditullio, M ;
Chu, E ;
Siedlecki, K ;
Verbel, D ;
Heller, G ;
Kelly, WK ;
Slovin, S ;
Schwartz, L ;
Scher, HI .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3210-3216
[5]   Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer [J].
Morris, MJ ;
Akhurst, T ;
Osman, I ;
Nunez, R ;
Macapinlac, H ;
Siedlecki, K ;
Verbel, D ;
Schwartz, L ;
Larson, SM ;
Scher, HI .
UROLOGY, 2002, 59 (06) :913-918
[6]   Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma [J].
Tiwari, B. P. ;
Jangra, S. ;
Nair, N. ;
Tongaonkar, H. B. ;
Basu, S. .
INDIAN JOURNAL OF CANCER, 2010, 47 (04) :385-390
1